42:I[185,["/_next/static/chunks/3xnt26d00_zk-.js","/_next/static/chunks/0gtn0si1crxii.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/06x30xgfe6iur.js","/_next/static/chunks/1pfyc3q3c61jb.js","/_next/static/chunks/35-gbipsuw5b6.js"],"SendEmailButton"] 44:I[63625,["/_next/static/chunks/3xnt26d00_zk-.js","/_next/static/chunks/0gtn0si1crxii.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/06x30xgfe6iur.js","/_next/static/chunks/1pfyc3q3c61jb.js","/_next/static/chunks/35-gbipsuw5b6.js"],"AddToLibraryButton"] 45:I[29721,["/_next/static/chunks/3xnt26d00_zk-.js","/_next/static/chunks/0gtn0si1crxii.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/06x30xgfe6iur.js","/_next/static/chunks/1pfyc3q3c61jb.js","/_next/static/chunks/35-gbipsuw5b6.js"],"ShareButton"] 46:I[58016,["/_next/static/chunks/3xnt26d00_zk-.js","/_next/static/chunks/0gtn0si1crxii.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/06x30xgfe6iur.js","/_next/static/chunks/1pfyc3q3c61jb.js","/_next/static/chunks/35-gbipsuw5b6.js"],"ProcessEpisodeButton"] 47:I[45269,["/_next/static/chunks/3xnt26d00_zk-.js","/_next/static/chunks/0gtn0si1crxii.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/06x30xgfe6iur.js","/_next/static/chunks/1pfyc3q3c61jb.js","/_next/static/chunks/35-gbipsuw5b6.js"],"SignupCTA"] 3a:["$","time",null,{"dateTime":"2026-05-19T14:00:00.000Z","children":"May 19, 2026"}] 3b:["$","span",null,{"aria-hidden":true,"children":"·"}] 3c:["$","span",null,{"children":"00:55:44"}] 43:T507,

A discectomy can feel like instant relief until the pain comes back, and the “small” hole in the disc turns into a repeat surgery, degeneration, and lost mobility. Joining the podcast is Greg Lambrecht, founder and executive director of Intrinsic Therapeutics, with host Geoff Pardo to unpack why recurrent lumbar disc herniation is still so common, what surgeons and patients often don’t see downstream, and how his team built Barricaid to address the problem at its source: the annular defect. They also discuss the engineering logic of a bone-anchored barrier and why early “optimal” designs failed inside a body that’s anything but gentle, as well as CMS versus private payer incentives and why trial protocols should be negotiated with reimbursement stakeholders early.

Subscribe and leave a review with your biggest question about getting breakthrough devices adopted.

LINKS:

Medtech Talk Links:
Cambridge Healthtech Institute
Medtech Talk
Gilde Healthcare

Intrinsic Therapeutics Links:
Barricaid